Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orphazyme A/S
Total Current Liabilities
Orphazyme A/S
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
Total Current Liabilities
kr5.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr1.4B
|
CAGR 3-Years
76%
|
CAGR 5-Years
47%
|
CAGR 10-Years
37%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr665m
|
CAGR 3-Years
50%
|
CAGR 5-Years
13%
|
CAGR 10-Years
25%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Current Liabilities
$1.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€1.1B
|
CAGR 3-Years
84%
|
CAGR 5-Years
83%
|
CAGR 10-Years
57%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr1.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
See Also
What is Orphazyme A/S's Total Current Liabilities?
Total Current Liabilities
5.1m
DKK
Based on the financial report for Dec 31, 2023, Orphazyme A/S's Total Current Liabilities amounts to 5.1m DKK.
What is Orphazyme A/S's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-37%
Over the last year, the Total Current Liabilities growth was -68%. The average annual Total Current Liabilities growth rates for Orphazyme A/S have been -69% over the past three years , -37% over the past five years .
